Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

http://www.wikidata.org/entity/Q36024588

about

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer Anti-angiogenic therapies for metastatic colorectal cancer Anti-angiogenic therapy for metastatic colorectal cancer Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Antiangiogenic mechanisms and factors in breast cancer treatment Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review The role of vascular endothelial growth factor a polymorphisms in breast cancer Lessons learned from the bevacizumab experience Anti-vascular endothelial growth factor therapy in breast cancer The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors Bevacizumab treatment for advanced breast cancer Bevacizumab in ovarian cancer: A critical review of phase III studies Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA Unraveling the microenvironmental influences on the normal mammary gland and breast cancer Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Phase II open-label study of sunitinib in patients with advanced breast cancer.Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.

P2860

Q24202199-4F118308-7C9F-4377-B0AA-610AE990C8EA Q24241813-0812229E-6B31-479B-A414-19BFBA4699FF Q24243297-EE344AE1-EB0F-4A1C-9074-7C204FC70EE6 Q26747666-2D426684-F83C-46DF-B15A-D750CE1E65D6 Q26751226-E67C5C71-C1F5-4288-9F94-86573B249E99 Q26786618-EBB977DE-1A10-49C6-B2C6-7870F63C78AA Q26822432-5F34D8CC-A3C2-47F7-A078-93F02FCB84CA Q26824086-E95D5779-5BAF-417E-B9F2-C15BB434BC41 Q26851522-0E9CA456-9B61-463A-BB5D-D8DE2282F490 Q26852509-7CAE79D2-7216-40F1-A1C7-FE469209C8D6 Q26999473-19579C0A-013F-4CE3-8415-BC7A52F0AE4E Q27011540-702D4203-BC33-418C-A1DA-4454DB1CC073 Q27027498-2B29FA00-A626-4DBF-8CC4-2B15076E954D Q28076188-4C1BDFC2-D2DC-45CF-B992-2094538AA202 Q28079013-3BF5A0D2-5559-4BBA-B571-40F56FE174F8 Q28087776-49CA5D42-96C9-48BC-B45F-7DD2659747D3 Q28219257-B1FA536D-E46A-4D55-A7D2-11B1455673B9 Q28472818-6DE7CF06-899E-4105-8BFF-B9FE336D419D Q28473677-D8AF915B-9337-422D-93FA-21459F5EE10E Q28555102-D5214665-8488-4C13-ACB4-C487D9FDF64F Q28749085-787A6EC4-6C10-4048-9419-8DFD23BA737E Q30248296-D3B03BA7-ECC4-4BBD-AE83-148A70D10F64 Q30249335-07778D73-42D7-4E8F-A199-9CE1011DB67E Q30317067-FAB51846-3FB5-4B4D-A5C9-7291C886C53F Q30358961-16D5A007-2468-4E2C-B58A-97CDE7FFB229 Q30390845-E18DFDAD-AE8A-4E87-9A79-DBA6A7E1A054 Q31060162-8EF645AD-CFA7-4AC7-B379-77CD9E4F025C Q31102468-A4971885-D72D-481E-9969-08E9370CFA08 Q31152878-B9BF2545-45CE-483E-B1BE-38C0CC218CF8 Q31157714-A0A1D864-3E4F-4CF5-80D7-79E803EDA494 Q33378298-2DC5912E-B9DE-4C28-B426-1A61E0C1DEA5 Q33392652-DAD65DAF-8C39-440F-9AFF-D55FEEE504DA Q33403848-B63581FD-4B48-468A-89D0-785B00C9784A Q33410746-94A54627-A1A9-49EC-A581-56221D639A5A Q33421880-8FA3CC6E-FB18-4A0B-BDB3-FF88DE3E7660 Q33422258-FCDC0A44-0011-4D19-AB20-6CA736BE2821 Q33424566-DC39B3A6-D1EF-45B7-A4FD-37B7624AC2AA Q33430813-BC06B44D-701F-4C1C-A8D3-9CA31DC8FBA5 Q33506194-CB2EC23A-ABF9-4616-9511-840D7E0A5A8D Q33516882-23962441-F1F4-4A43-B5A2-F47F80FD8B2F

P2860

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

http://www.wikidata.org/entity/Q36024588

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Randomized phase III trial of ...... ated metastatic breast cancer.

@ast

Randomized phase III trial of ...... ated metastatic breast cancer.

@en

type

label

Randomized phase III trial of ...... ated metastatic breast cancer.

@ast

Randomized phase III trial of ...... ated metastatic breast cancer.

@en

prefLabel

Randomized phase III trial of ...... ated metastatic breast cancer.

@ast

Randomized phase III trial of ...... ated metastatic breast cancer.

@en

P1433

Q36024588-77D9CDE1-B94D-48D2-8C6F-E42B5652BB5B

P1476

Q36024588-E22F399B-5C75-43A3-A82E-8A46DD73F469

P2093

Q36024588-0A70713A-7654-4FDC-B380-866B5DE67012

Q36024588-796B1419-C688-42C4-8896-1BFCE889D290

Q36024588-8089AFC0-D1AB-4EEB-8541-C69D6E8CB11F

Q36024588-868298BA-43CF-4317-A906-15BF598787E9

Q36024588-89796A12-BDA6-43F7-8729-A4246124B5BF

Q36024588-B616B887-DE41-40FC-9E5A-57C17EDA1882

Q36024588-C381852B-CAB6-43EB-A96A-D4759ABF8987

Q36024588-D35C115B-29D0-4398-B342-D565D6496BE2

Q36024588-D49D6196-F277-4C97-B816-D1738FE5F3FC

Q36024588-D58B9CAE-18B6-479A-B7B1-C2AAC00E5C05

P304

Q36024588-DBE89FFB-89B7-403F-BE8B-1957ADF1F855

P31

Q36024588-8E455B96-10D9-4739-9E4F-08A2B21A9E96

P356

Q36024588-2BFFCC8E-970A-4C13-900A-5ADB851768E8

P407

Q36024588-6F701CEA-6E79-4F04-A081-F21F8B8CD188

P433

Q36024588-272D0B95-0A3E-4C88-B2DA-E4101CAF8BFB

P478

Q36024588-6A660AB1-41D9-4919-91EF-1711587B3E43

P577

Q36024588-8D74EC0E-5D99-498F-AE1F-8F149A85CA82

P698

Q36024588-EEA3799F-85ED-4A21-AA06-CEB9B1626EB8

P921

Q36024588-44E71ED2-2A60-4912-8598-31273F06B04C

Q36024588-6D72F808-0DA4-4FB1-8815-D6A8B577BEAE

P356

JCO.2005.05.098

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... ated metastatic breast cancer.

@en

P2093

Amy P Sing

http://www.w3.org/2001/XMLSchema#string

Beth A Overmoyer

http://www.w3.org/2001/XMLSchema#string

Frankie A Holmes

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

James D Reimann

http://www.w3.org/2001/XMLSchema#string

Kathy D Miller

http://www.w3.org/2001/XMLSchema#string

Linnea I Chap

http://www.w3.org/2001/XMLSchema#string

Louis Fehrenbacher

http://www.w3.org/2001/XMLSchema#string

Maura Dickler

http://www.w3.org/2001/XMLSchema#string

Melody A Cobleigh

http://www.w3.org/2001/XMLSchema#string

P304

792-799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.098

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15681523

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial